| 產(chǎn)品名稱 | PCI 32765 - Ibrutinib |
| 產(chǎn)品貨號(hào) | Axon 1858 CAS [936563-96-1] MF C25H24N6O2MW 440.50 Purity: 99% Soluble in DMSO Description Orally bioavailable and highly selective inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity; inhibiting BTK activity, B-cell-mediated signaling and the growth of malignant B cells that overexpress BTK; an experimental drug candidate for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma etcBTK, a member of the BTK/Tec family of non-recetor cytoplasmic tyrosine kinases, is required for B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies References Certificates Categories Extra info Z Pan et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(1), 58–61.? ? LA Honigberg et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Nat. Acad. Sci. USA 2010, 107(29), 13075–80.? ? ES Winer et al. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs. 2012, 21(3), 355-61.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Immunology BTK EC 2.7.10.2 Inhibitor of Bruton's tyrosine kinase (BTK) Chemical name (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one Parent CAS No. [936563-96-1] Order Size Unit Price Stock 5 mg €95.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
PCI 32765 - IbrutinibAxon 1858 CAS [936563-96-1] MF C25H24N6O2
Description
Orally bioavailable and highly selective inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity; inhibiting BTK activity, B-cell-mediated signaling and the growth of malignant B cells that overexpress BTK; an experimental drug candidate for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma etcBTK, a member of the BTK/Tec family of non-recetor cytoplasmic tyrosine kinases, is required for B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies
Inhibitor of Bruton's tyrosine kinase (BTK)
Chemical name(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one Parent CAS No.[936563-96-1] |
| 產(chǎn)品資料 |
